Elanco Animal Health Inc
ELAN
View Detailed Chart
19.200USD
+0.100+0.52%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
9.54BMarket Cap
21.97P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.52%
5 Days
+3.62%
1 Month
+9.59%
6 Months
+77.29%
Year to Date
+58.55%
1 Year
+27.41%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated: 2025-09-19Key Insights
The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
15
analysts
Buy
Current Rating
18.700
Target Price
-2.09%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Elanco Animal Health Incorporated is an animal health company. The Company is focused on delivering products and services to prevent and treat disease in farm animals and pets. Its diverse, durable product portfolio serves animals across many species, primarily: dogs, cats and cattle, poultry, swine, and sheep. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio has products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, and poultry. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD 338.00M.%!(EXTRA int=2)
Overvalued
The company’s latest PE is 21.87, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 515.44M shares, decreasing 7.31% quarter-over-quarter.
Held by Van Duyn Dodge & E. Morris Cox
Star Investor Van Duyn Dodge & E. Morris Cox holds 82.90M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.06.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Elanco Animal Health Incorporated is an animal health company. The Company is focused on delivering products and services to prevent and treat disease in farm animals and pets. Its diverse, durable product portfolio serves animals across many species, primarily: dogs, cats and cattle, poultry, swine, and sheep. It offers products in two primary categories: Pet Health and Farm Animal. Its Pet Health portfolio is focused on parasiticides, vaccines and therapeutics. Its Pet Health portfolio has products that protect pets from fleas, ticks and internal parasites. Its Farm Animal portfolio of products is primarily focused on cattle, swine, and poultry. Its Pet Health products include Advantage Family, Atopica, Claro/ Neptra, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its Farm Animal products include AviPro, Baycox, Catosal, Comforta, Denagard, Experior, Hemicell, Maxiban, Monteban, Pulmotil, Rumensin, and others.
Ticker SymbolELAN
CompanyElanco Animal Health Inc
CEOMr. Jeffrey N. (Jeff) Simmons
Websitehttps://www.elanco.com/
Related Instruments
-1.43%
+1.17%
+0.22%
+0.52%
-1.03%
-0.73%
-0.02%
+3.47%
+0.41%
-0.50%
-0.08%
-1.03%
-1.27%
+1.19%
+0.92%
-0.87%
-0.23%
-0.83%
-1.12%
+0.31%
